Abstract
Editorial commentDermatology trainees need to be familiar with azathioprine as this drug is an important immunosuppressive agent used in a variety of different dermatological conditions. This article covers both the licensed and unlicensed indications for azathioprine and outlines the metabolic fate of this drug in relation to safety and efficacy. Guidelines concerning pre-treatment counselling of patients, dosage and monitoring for side-effects are included. Trainees should be aware that long-term use of azathioprine has been implicated as a co-factor in the development of skin neoplasia and in non-cutaneous malignancy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
